Targeted Therapies vs Chemotherapy in MAPK-Pathway Altered Histiocytic Neoplasms | ECDGA 2025 скачать в хорошем качестве

Targeted Therapies vs Chemotherapy in MAPK-Pathway Altered Histiocytic Neoplasms | ECDGA 2025

This session from the Medical Symposium at ECDGA 2025 in Barcelona, Spain (Day Two, May 27, 2025) features Carla Isabel Borre, Mayo Clinic, Rochester, MN, USA, presenting on the topic: Comparative Efficacy of Frontline Targeted Therapies Versus Chemotherapy in MAPK-Pathway Altered Histiocytic Neoplasms. Dr. Borre provides an in-depth analysis of treatment outcomes in patients with histiocytic neoplasms, exploring the evolving role of frontline targeted therapies compared with traditional chemotherapy. The presentation highlights efficacy, safety, and clinical implications for managing MAPK-pathway altered disease, offering valuable insights for oncologists, hematologists, pathologists, and researchers focused on precision medicine in rare neoplasms. This video is part of the Medical Symposium program of ECDGA 2025, which brought together global experts to discuss advances in diagnostics, therapies, and patient outcomes in histiocytic disorders. For more sessions and the full agenda, visit the ECDGA official program.